admin
Admin
posted on
— updated on
AMT-101, an oral candidate for ulcerative colitis from Applied Molecular Transport (AMTI), has failed in a phase 2 trial.
Applied Molecular Transport oral ulcerative colitis candidate fails in mid-stage trialDec. 22, 2022 6:19 PM ETApplied Molecular Transport Inc. (AMTI)By: Jonathan Block, SA News Editor
Comments
0 comment